Logo image of EPRX.CA

EUPRAXIA PHARMACEUTICALS INC (EPRX.CA) Stock Fundamental Analysis

Canada - Toronto Stock Exchange - TSX:EPRX - CA29842P1053 - Common Stock

9.11 CAD
+0.41 (+4.71%)
Last: 12/19/2025, 7:00:00 PM
Fundamental Rating

3

Taking everything into account, EPRX scores 3 out of 10 in our fundamental rating. EPRX was compared to 23 industry peers in the Biotechnology industry. While EPRX has a great health rating, there are worries on its profitability. EPRX has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year EPRX has reported negative net income.
EPRX had a negative operating cash flow in the past year.
EPRX had negative earnings in each of the past 5 years.
EPRX had a negative operating cash flow in each of the past 5 years.
EPRX.CA Yearly Net Income VS EBIT VS OCF VS FCFEPRX.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M

1.2 Ratios

EPRX's Return On Assets of -31.81% is fine compared to the rest of the industry. EPRX outperforms 65.22% of its industry peers.
Looking at the Return On Equity, with a value of -32.63%, EPRX is in the better half of the industry, outperforming 78.26% of the companies in the same industry.
Industry RankSector Rank
ROA -31.81%
ROE -32.63%
ROIC N/A
ROA(3y)-100.7%
ROA(5y)-130.32%
ROE(3y)-510.2%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
EPRX.CA Yearly ROA, ROE, ROICEPRX.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 1K -1K -2K

1.3 Margins

EPRX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
EPRX.CA Yearly Profit, Operating, Gross MarginsEPRX.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

8

2. Health

2.1 Basic Checks

The number of shares outstanding for EPRX has been increased compared to 1 year ago.
Compared to 5 years ago, EPRX has more shares outstanding
There is no outstanding debt for EPRX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
EPRX.CA Yearly Shares OutstandingEPRX.CA Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
EPRX.CA Yearly Total Debt VS Total AssetsEPRX.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

2.2 Solvency

EPRX has an Altman-Z score of 84.31. This indicates that EPRX is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of EPRX (84.31) is better than 100.00% of its industry peers.
There is no outstanding debt for EPRX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 84.31
ROIC/WACCN/A
WACCN/A
EPRX.CA Yearly LT Debt VS Equity VS FCFEPRX.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M

2.3 Liquidity

EPRX has a Current Ratio of 23.98. This indicates that EPRX is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 23.98, EPRX belongs to the top of the industry, outperforming 95.65% of the companies in the same industry.
A Quick Ratio of 23.98 indicates that EPRX has no problem at all paying its short term obligations.
EPRX has a Quick ratio of 23.98. This is amongst the best in the industry. EPRX outperforms 95.65% of its industry peers.
Industry RankSector Rank
Current Ratio 23.98
Quick Ratio 23.98
EPRX.CA Yearly Current Assets VS Current LiabilitesEPRX.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

More info and screens

1

3. Growth

3.1 Past

EPRX shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -6.65%.
EPS 1Y (TTM)-6.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-12.93%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, EPRX will show a quite strong growth in Earnings Per Share. The EPS will grow by 13.16% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y18.44%
EPS Next 2Y12.24%
EPS Next 3Y17%
EPS Next 5Y13.16%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPRX.CA Yearly Revenue VS EstimatesEPRX.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 2028 2029 2030 2031 2032 100M 200M 300M
EPRX.CA Yearly EPS VS EstimatesEPRX.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 -1 2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for EPRX. In the last year negative earnings were reported.
Also next year EPRX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
EPRX.CA Price Earnings VS Forward Price EarningsEPRX.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
EPRX.CA Per share dataEPRX.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2

4.3 Compensation for Growth

A more expensive valuation may be justified as EPRX's earnings are expected to grow with 17.00% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y12.24%
EPS Next 3Y17%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for EPRX!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

EUPRAXIA PHARMACEUTICALS INC

TSX:EPRX (12/19/2025, 7:00:00 PM)

9.11

+0.41 (+4.71%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-04 2025-11-04/amc
Earnings (Next)N/A N/A
Inst Owners37.29%
Inst Owner ChangeN/A
Ins Owners17.49%
Ins Owner ChangeN/A
Market Cap461.42M
Revenue(TTM)N/A
Net Income(TTM)-29.37M
Analysts84
Price Target12.36 (35.68%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-30.08%
Min EPS beat(2)-41.57%
Max EPS beat(2)-18.58%
EPS beat(4)0
Avg EPS beat(4)-41.02%
Min EPS beat(4)-80.04%
Max EPS beat(4)-18.58%
EPS beat(8)3
Avg EPS beat(8)-23.25%
EPS beat(12)7
Avg EPS beat(12)-9.73%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)10.12%
PT rev (3m)10.12%
EPS NQ rev (1m)3.79%
EPS NQ rev (3m)3.79%
EPS NY rev (1m)-2.49%
EPS NY rev (3m)20.46%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 3.72
P/tB 3.72
EV/EBITDA N/A
EPS(TTM)-1.66
EYN/A
EPS(NY)-1.05
Fwd EYN/A
FCF(TTM)-0.69
FCFYN/A
OCF(TTM)-0.68
OCFYN/A
SpS0
BVpS2.45
TBVpS2.45
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -31.81%
ROE -32.63%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-100.7%
ROA(5y)-130.32%
ROE(3y)-510.2%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 214.74%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 23.98
Quick Ratio 23.98
Altman-Z 84.31
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)106.53%
Cap/Depr(5y)142.1%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-6.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-12.93%
EPS Next Y18.44%
EPS Next 2Y12.24%
EPS Next 3Y17%
EPS Next 5Y13.16%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y38.02%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year2.36%
EBIT Next 3Y-2.11%
EBIT Next 5Y16.98%
FCF growth 1Y-0.11%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y1.17%
OCF growth 3YN/A
OCF growth 5YN/A

EUPRAXIA PHARMACEUTICALS INC / EPRX.CA FAQ

What is the fundamental rating for EPRX stock?

ChartMill assigns a fundamental rating of 3 / 10 to EPRX.CA.


Can you provide the valuation status for EUPRAXIA PHARMACEUTICALS INC?

ChartMill assigns a valuation rating of 0 / 10 to EUPRAXIA PHARMACEUTICALS INC (EPRX.CA). This can be considered as Overvalued.


Can you provide the profitability details for EUPRAXIA PHARMACEUTICALS INC?

EUPRAXIA PHARMACEUTICALS INC (EPRX.CA) has a profitability rating of 1 / 10.


How financially healthy is EUPRAXIA PHARMACEUTICALS INC?

The financial health rating of EUPRAXIA PHARMACEUTICALS INC (EPRX.CA) is 8 / 10.